Key result
Activation of P2Y2 purinergic receptors with ATP or Diquafosol tetrasodium rescued endothelial dysfunction, restored cerebrovascular reactivity, and improved autism-associated behaviors in a 16p11.2 deletion mouse model.
Why the study?
Postnatal brain endothelial abnormalities occur in 16p11.2 deletion mice, but the specific endothelial alterations eliciting these changes remain unknown.
Does purinergic receptor activation improve endothelial function and ASD-associated behaviors in a 16p11.2 deletion mouse model?
Does purinergic receptor activation improve endothelial function and ASD-associated behaviors in a 16p11.2 deletion mouse model?
This is the authors' abstract. We don't add key points for this paper.
Early cerebrovascular alterations affect brain maturation by impacting trophic support and energy supply. Recent evidence in a 16p11.2 deletion mouse model of autism spectrum disorder (ASD) revealed brain endothelial abnormalities postnatally. Yet, the endothelial alterations eliciting these changes remain unknown. Isolation of brain endothelial cells (ECs) from 14-day old male 16p11.2-deficient and wild-type mice revealed that 16p11.2 deletion-induced endothelial dysfunction is linked to a bioenergetic failure, with reduced intracellular ATP. Intra- or extra-cellular ATP supplementation rescued the function of 16p11.2-deficient ECs in vitro via P2 purinergic receptor activation, specifically P2Y2 receptors. Activating P2Y2 receptors restored cerebrovascular reactivity in 16p11.2-deficient parenchymal arterioles ex vivo and rescued 16p11.2 deletion-associated mouse behaviors. Taken together, this study demonstrates that metabolic reprogramming of brain ECs via purinergic receptor engagement represents a possible therapeutic avenue for ASD.
Answers are grounded in this paper and cite their sources.
Metabolic reprogramming of brain endothelial cells via purinergic receptor engagement represents a possible therapeutic avenue for autism spectrum disorder.
No takes yet. Share an insight, caveat, or question.
Ouellette et al. (2025) studied Autism spectrum disorder (16p11.2 deletion syndrome). Purinergic receptor activation (ATP supplementation or P2Y2 agonist Diquafosol tetrasodium) vs. Wild-type mice or vehicle/PBS-treated 16p11.2-deficient mice was evaluated on Endothelial function (angiogenic capacity, cerebrovascular reactivity) and ASD-related behaviors. Activation of P2Y2 purinergic receptors with ATP or Diquafosol tetrasodium rescued endothelial dysfunction, restored cerebrovascular reactivity, and improved autism-associated behaviors in a 16p11.2 deletion mouse model.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: